(MedPage Today) — SAN FRANCISCO — For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical prostatectomy, a randomized…
Source link : https://www.medpagetoday.com/meetingcoverage/astro/117701
Author :
Publish date : 2025-09-29 20:20:00
Copyright for syndicated content belongs to the linked Source.
